Pfizer Inc. vs Eli Lilly & Co.
PFE vs LLY — side-by-side comparison from reported financials. PFE leads 2, LLY leads 10 of 12 comparable metrics.
Pfizer Inc.
PFE · Healthcare
$28.27+1.62%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | PFE | LLY |
|---|---|---|
| Price | $28.27 | $1 177.20 |
| Market cap | $161B | $1.05T |
| Revenue (TTM) | $63.7B | $79.7B |
| Revenue growth | -14.8% | +31.7% |
| Net margin | 6.8% | 33.5% |
| Free cash flow | $11.0B | $18.2B |
| Net cash (debt) | ($51.6B) | ($35.2B) |
| 1-year price return | +12.0% | +37.6% |
| P/E | 37.2 | 41.6 |
| P/E vs own history (cheap-side %) | 4% | 88% |
| Dividend yield | 6.07% | 0.52% |
| Return on equity | 5% | 93% |
| Altman Z-score | 1.96 | 7.10 |
| CV checks passed | 9 of 11 | 11 of 11 |
| Employees | 75,000 | 50,000 |
Full résumé-style profiles: PFE CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.